Build quality in - HER2 testing in the real world

被引：10

作者：

Zujewski, JA ^{[1
]}

机构：

[1] NCI, Ctr Canc Res, NIH, Med Branch, Bethesda, MD 20892 USA

来源：

JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2002年 / 94卷 / 11期

关键词：

D O I：

10.1093/jnci/94.11.788

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：788 / 789

页数：2

共 19 条

[1] HER-2/NEU IN NODE-NEGATIVE BREAST-CANCER - PROGNOSTIC-SIGNIFICANCE OF OVEREXPRESSION INFLUENCED BY THE PRESENCE OF INSITU CARCINOMA [J].

ALLRED, DC ;

CLARK, GM ;

TANDON, AK ;

MOLINA, R ;

TORMEY, DC ;

OSBORNE, CK ;

GILCHRIST, KW ;

MANSOUR, EG ;

ABELOFF, M ;

EUDEY, L ;

MCGUIRE, WL .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :599-605

[2] neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer [J].

Andrulis, IL ;

Bull, SB ;

Blackstein, ME ;

Sutherland, D ;

Mak, C ;

Sidlofsky, S ;

Pritzker, KPH ;

Hartwick, RW ;

Hanna, W ;

Lickley, L ;

Wilkinson, R ;

Qizilbash, A ;

Ambus, U ;

Lipa, M ;

Weizel, H ;

Katz, A ;

Baida, M ;

Mariz, S ;

Stoik, G ;

Dacamara, P ;

Strongitharm, D ;

Geddie, W ;

McCready, D .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1340-1349

[3] c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases [J].

Carlomagno, C ;

Perrone, F ;

Gallo, C ;

DeLaurentiis, M ;

Lauria, R ;

Morabito, A ;

Pettinato, G ;

Panico, L ;

DAntonio, A ;

Bianco, AR ;

DePlacido, S .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) :2702-2708

[4] Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status? [J].

Clark, GM .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18) :1320-1321

[5] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].

Cobleigh, MA ;

Vogel, CL ;

Tripathy, D ;

Robert, NJ ;

Scholl, S ;

Fehrenbacher, L ;

Wolter, JM ;

Paton, V ;

Shak, S ;

Lieberman, G ;

Slamon, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648

[6] TYROSINE KINASE RECEPTOR WITH EXTENSIVE HOMOLOGY TO EGF RECEPTOR SHARES CHROMOSOMAL LOCATION WITH NEU ONCOGENE [J].

COUSSENS, L ;

YANGFENG, TL ;

LIAO, YC ;

CHEN, E ;

GRAY, A ;

MCGRATH, J ;

SEEBURG, PH ;

LIBERMANN, TA ;

SCHLESSINGER, J ;

FRANCKE, U ;

LEVINSON, A ;

ULLRICH, A .

SCIENCE, 1985, 230 (4730) :1132-1139

[7]

CRAWFORDMASON C, 2002, WASHINGTON POST 0423, pHE1

[8]

Elledge RM, 1998, CLIN CANCER RES, V4, P7

[9] PROGNOSTIC IMPORTANCE OF C-ERBB-2 EXPRESSION IN BREAST-CANCER [J].

GUSTERSON, BA ;

GELBER, RD ;

GOLDHIRSCH, A ;

PRICE, KN ;

SAVESODERBORGH, J ;

ANBAZHAGAN, R ;

STYLES, J ;

RUDENSTAM, CM ;

GOLOUH, R ;

REED, R ;

MARTINEZTELLO, F ;

TILTMAN, A ;

TORHORST, J ;

GRIGOLATO, P ;

BETTELHEIM, R ;

NEVILLE, AM ;

BURKI, K ;

CASTIGLIONE, M ;

COLLINS, J ;

LINDTNER, J ;

SENN, HJ .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (07) :1049-1056

[10] PATHOLOGICAL FINDINGS FROM THE NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT - PROGNOSTIC-SIGNIFICANCE OF ERBB-2 PROTEIN OVEREXPRESSION IN PRIMARY BREAST-CANCER [J].

PAIK, S ;

HAZAN, R ;

FISHER, ER ;

SASS, RE ;

FISHER, B ;

REDMOND, C ;

SCHLESSINGER, J ;

LIPPMAN, ME ;

KING, CR .

JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (01) :103-112

← 1 2 →